No Data
No Data
Spyre Therapeutics Advances SPY003 for IBD Treatment
Paragon Therapeutics Granted Spyre Therapeutics An Exclusive License To Develop, Manufacture, And Commercialize Certain Antibodies And Products Targeting IL-23 For Irritable Bowel Disease, Paragon Will Receive $22M As Milestone Payments And Further...
Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)
Express News | Spyre Therapeutics Inc : Jefferies Raises Target Price to $37 From $31